Supplementary Table 5. Hazard ratios and 95% confidence intervals for development of metabolic syndrome according to percent change in serum uric acid level as a continuous variable, regarding to the quartile categories of the basal serum uric acid level: female

	Baseline serum uric acid (female, *n*=5,363)							
	Quartile 1 (≤3.5 mg/dL, *n*=1,392; continuous variable [1SD])	*P* value	Quartile 2 (3.6–4.0 mg/dL, *n*=1,259; continuous variable [1SD])	*P* value	Quartile 3 (4.1–4.6 mg/dL, *n*=1,449; continuous variable [1SD])	*P* value	Quartile 4 (≥4.7 mg/dL, *n*=1,263; continuous variable [1SD])	*P* value
Incident MetS	151 (10.8)		169 (13.4)		253 (17.5)		328 (26.0)	
Unadjusted	0.817 (0.719–0.929)	0.002	0.948 (0.824–1.090)	0.451	0.895 (0.791–1.012)	0.076	0.844 (0.755–0.944)	0.003
Model 1	0.829 (0.732–0.940)	0.003	0.893 (0.784–1.019)	0.093	0.919 (0.813–1.040)	0.180	0.840 (0.752–0.939)	0.002
Model 2	0.819 (0.722–0.930)	0.002	0.869 (0.759–0.995)	0.043	0.869 (0.768–0.983)	0.025	0.833 (0.745–0.931)	0.001
Model 3	0.825 (0.726–0.939)	0.004	0.868 (0.758–0.994)	0.041	0.871 (0.770–0.986)	0.029	0.843 (0.752–0.944)	0.003
Model 4	0.833 (0.706–0.985)	0.032	0.842 (0.708–1.000)	0.050	0.839 (0.717–0.983)	0.030	0.832 (0.715–0.967)	0.017

Values are presented as number (%) or hazard ratio (95% confidence interval). Model 1: adjusted for age, systolic blood pressure, body mass index, fat-free mass (%), estimated glomerular filtration rate, and smoking status; Model 2: adjusted for Model 1 plus fasting glucose, triglyceride, low density lipoprotein cholesterol, and high density lipoprotein cholesterol; Model 3: adjusted for Model 2 plus baseline serum uric acid; Model 4: adjusted for Model 3 plus fasting insulin.[a]

MetS, metabolic syndrome.

[a]*n*=2,792 female.